Premium Nahrungsergänzungsmittel | artgerecht

Pitavastatin: Effects, Dosage and Side Effects

Pitavastatin is a prescription statin medication used to lower elevated cholesterol levels and reduce the risk of cardiovascular disease.

Regular tips about health Regular tips about health

Things worth knowing about "Pitavastatin"

Pitavastatin is a prescription statin medication used to lower elevated cholesterol levels and reduce the risk of cardiovascular disease.

What is Pitavastatin?

Pitavastatin is an active substance belonging to the class of statins (HMG-CoA reductase inhibitors). It is used to treat elevated blood lipid levels, specifically primary hypercholesterolaemia and mixed dyslipidaemia. By lowering LDL cholesterol (often referred to as “bad” cholesterol), pitavastatin helps reduce the risk of heart attack, stroke, and other cardiovascular events. It is a newer-generation statin available under various brand names worldwide, including Livazo and Zypitamag.

Mechanism of Action

Pitavastatin competitively inhibits the enzyme HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase), which plays a key role in cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces the amount of cholesterol produced by the liver. In response, the liver upregulates the number of LDL receptors on its cell surface, increasing the clearance of LDL cholesterol from the bloodstream. This leads to a significant reduction in circulating LDL levels.

A notable pharmacological feature of pitavastatin is its minimal metabolism via the cytochrome P450 (CYP) enzyme system. Unlike many other statins, it is only minimally metabolised by CYP2C9 and is not metabolised by CYP3A4, resulting in a lower potential for drug-drug interactions.

Indications

Primary hypercholesterolaemia (elevated LDL cholesterol)
Mixed dyslipidaemia (elevated LDL and triglycerides combined with low HDL cholesterol)
Adjunct to dietary measures in patients at increased cardiovascular risk
Primary and secondary prevention of cardiovascular events

Dosage and Administration

Pitavastatin is taken orally as a tablet, usually once daily, with or without food. The standard starting dose is 1 mg to 2 mg per day. The dose may be increased to a maximum of 4 mg per day depending on the patient's lipid profile, treatment goals, and tolerability. Dose adjustments are required in patients with moderate to severe renal impairment or hepatic conditions.

Treatment is long-term and should always be accompanied by lifestyle modifications, including a low-cholesterol diet, regular physical activity, and weight management.

Side Effects

Pitavastatin is generally well tolerated. However, as with all statins, side effects may occur:

Common side effects: Muscle pain (myalgia), headache, constipation, nausea
Uncommon side effects: Elevated liver enzymes, back pain, dizziness
Rare but serious side effects: Myopathy (muscle disease) and, in severe cases, rhabdomyolysis (breakdown of muscle tissue that may lead to kidney failure) – patients should seek immediate medical attention if they experience unexplained or severe muscle pain, weakness, or tenderness
Slight increase in blood glucose levels and a marginally elevated risk of type 2 diabetes have been reported with statin use in general

Contraindications and Drug Interactions

Pitavastatin must not be used in patients with:

Active liver disease or unexplained persistent elevations in liver enzymes
Pregnancy or breastfeeding (statins are contraindicated during pregnancy)
Known hypersensitivity to pitavastatin or any excipient of the formulation

Clinically relevant drug interactions include:

Ciclosporin: Concomitant use is contraindicated due to a significant increase in pitavastatin plasma concentrations
Fibrates (e.g. gemfibrozil): Increased risk of myopathy when combined with statins
Erythromycin and other macrolide antibiotics: May increase pitavastatin plasma levels

References

European Medicines Agency (EMA): Pitavastatin Product Information, EPAR Database, www.ema.europa.eu
Catapano AL et al. - 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016; 37(39): 2999-3058.
Budinski D et al. - Pitavastatin compared with atorvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Clinical Drug Investigation, 2009; 29(3): 143-153.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.